Skip to content

EBITDA at other companies

Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
$17.8M+75.8%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$111.74M-55.0%
Biohaven logo
BiohavenBHVN
-$128.06M+41.6%
Septerna, Inc. logo
Septerna, Inc.SEPN
-$12.88M+49.5%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$24.2M+10.7%
Net income-$19.9M+17.5%
EPS (diluted)-$0.42+38.2%

Balance sheet

See full
Cash & equivalents$78.1M+35.5%
Total debt$10.8M+37.8%
Total equity$471.5M+65.0%
Total assets$497.6M+64.7%

Cash flow

See full
Operating cash flow-$13.1M+35.5%
CapEx$86.0K-70.4%
Free cash flow-$13.1M+36.0%

Valuation

See full
Market cap$1.91B+309%

Returns & leverage

See full
Return on equity-28.3%
Debt / equity0.0×
Current ratio27.1×-3.9×

Where this comes from

Calculated from Rapport Therapeutics, Inc.’s reported figures.

$24.2Mebit+
$227.0KDepreciation Depletion & Amortization
=-$23.99M

The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapport Therapeutics, Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rapport Therapeutics, Inc.'s EBITDA?
Rapport Therapeutics, Inc. (RAPP) reported EBITDA of -$23.99M in Q1 2026.
How has Rapport Therapeutics, Inc.'s EBITDA changed year-over-year?
Rapport Therapeutics, Inc.'s EBITDA increased by 10.7% year-over-year, from -$26.86M to -$23.99M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.